Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin

Internal Medicine Journal

Volumn 37, Issue 2, 2007, Pages 79-86

  Derosa, G ^a   D'Angelo, A ^a   Ragonesi, P D ^b   Ciccarelli, L ^a   Piccinni, M N ^a   Pricolo, F ^a   Salvadeo, S A T ^a   Montagna, L ^a   Gravina, A ^a   Ferrari, I ^a   Paniga, S ^a   Cicero, A F G ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Lipid; Metabolic syndrome; Thiazolidinedione; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 33846092585     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01238.x     Document Type: Article

References (26)

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002; 25(Suppl. 1): S1-S147.
2. Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003; 46(Suppl. 1): M44-M50.
3. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108(Suppl. 6A): 15S-22S.
4. Vague P. Is metformin more than an oral hypoglycaemic agent? Diabetes Metab 2003; 29: 6S5-7.
5. Johnson JA, Simpson SH, Majumdar SR, Toth EL. Decreased mortality associated with the use of metformin compared with sulphanylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 253: 854-65.
7. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
8. Stumvoll M. Thiazolidinediones - some recent developments. Expert Opin Investig Drugs 2003; 12: 1179-87.
9. American Diabetes Association. Screening for diabetes (Position Statement). Diabetes Care 2001; 24(Suppl.): S21-4.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
11. WHO. International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-83.
12. WHO. Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity. Geneva: WHO; 1997 Jun.
13. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (position statement). Diabetes Care 2001; 24(Suppl.): S44-7.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
15. Winer BJ. Statistical Principles in Experimental Design, 2nd edn. New York: McGraw-Hill; 1971.
16. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004; 26: 2066-75.
17. Bailey CJ, Day C. Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. Int J Clin Pract 2004; 58: 867-76.
18. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21: 167-74.
19. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-54.
20. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-96.
21. LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002; 18: 363-70.
22. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-24.
23. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-9.
24. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40-47.
25. Menotti A, Lanti MP, Puddu PE. Twenty-five-year cardiovascular disease incidence among middle-aged men. Disease burden, time shape, predictors, risk probabilities. Ital Heart J 2000; 1: 749-57.
26. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373-405.